FDA approves Celgene drug for pancreatic cancer

September 7, 2013

Federal regulators have approved Celgene Inc.'s drug Abraxane to treat late-stage pancreatic cancer.

In experimental trials, the drug extended the lives of patients by a little less than two months more than those treated with the current standard drug.

Abraxane is already approved to treat and a type of lung cancer. It accounted for $155 million in revenue for Celgene in the second quarter.

Pancreatic cancer is considered especially deadly and hard to treat. It typically causes few symptoms until it has spread enough that it can't be surgically removed.

The National Cancer Institute estimates about 45,000 patients will be diagnosed and about 38,000 will die from the disease this year.

Explore further: Abraxane approved to treat advanced lung cancer

Related Stories

Abraxane approved to treat advanced lung cancer

October 14, 2012

(HealthDay)—Abraxane (paclitaxel protein-bound) has been approved by the U.S. Food and Drug Administration—in combination with the drug carboplatin—to treat advanced or spreading non-small cell lung cancer among people ...

FDA approves genetic test for lung cancer drug

May 14, 2013

The Food and Drug Administration says it approved a genetic test from Roche to help doctors identify patients who can benefit from a lung cancer drug made by Genentech.

Recommended for you

Researchers thwart cancer cells by triggering 'virus alert'

August 27, 2015

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system "virus alert" that may one day boost cancer patients' ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.